Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2026-03-08 @ 3:39 AM
Study NCT ID:
NCT04111705
Status:
COMPLETED
Last Update Posted:
2025-04-01
First Post:
2019-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IFCT-1902
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None